WallStreetZenWallStreetZen

NASDAQ: TVTX
Travere Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

TVTX past revenue growth

How has TVTX's revenue growth performed historically?
Company
32.69%
Industry
151.46%
Market
17.61%
TVTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
TVTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
TVTX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

TVTX earnings and revenue history

Current Revenue
$145.2M
Current Earnings
-$111.4M
Current Profit Margin
-76.7%

TVTX Return on Equity

Current Company
-56.7%
Current Industry
-63.5%
Current Market
188%
TVTX's Return on Equity (-56.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when TVTX announces earnings.

TVTX Return on Assets

Current Company
-14.1%
Current Industry
2.9%
TVTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

TVTX Return on Capital Employed

Current Company
-16.34%
Current Industry
19.5%
TVTX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TVTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
TVTX$145.24M-$61.31M-$111.40M-2.43%N/A
TBPH$57.42M-$40.77M-$55.19M-1.00%N/A
FULC$2.81M-$95.16M-$97.34M-88.03%N/A
IGMS$2.13M-$232.05M-$246.42M+99.25%N/A
TSHA$15.45M-$104.02M-$111.57M+517.55%N/A
View Top Biotech Stocks

TVTX earnings dates

Next earnings date
May 2, 2024

Travere Therapeutics Earnings & Revenue FAQ

What were TVTX's earnings last quarter?

On Invalid Date, Travere Therapeutics (NASDAQ: TVTX) reported Q4 2023 earnings per share (EPS) of -$1.21, up 17.48% year over year. Total Travere Therapeutics earnings for the quarter were -$90.17 million. In the same quarter last year, Travere Therapeutics's earnings per share (EPS) was -$1.03.

If you're new to stock investing, here's how to buy Travere Therapeutics stock.

What was TVTX's earnings growth in the past year?

As of Q2 2024, Travere Therapeutics's earnings has grown year over year. Travere Therapeutics's earnings in the past year totalled -$111.40 million.

What is TVTX's earnings date?

Travere Therapeutics's earnings date is Invalid Date. Add TVTX to your watchlist to be reminded of TVTX's next earnings announcement.

What was TVTX's revenue last quarter?

On Invalid Date, Travere Therapeutics (NASDAQ: TVTX) reported Q4 2023 revenue of $45.06 million up 53.58% year over year. In the same quarter last year, Travere Therapeutics's revenue was $29.34 million.

What was TVTX's revenue growth in the past year?

As of Q2 2024, Travere Therapeutics's revenue has grown 32.69% year over year. This is 118.77 percentage points lower than the US Biotechnology industry revenue growth rate of 151.46%. Travere Therapeutics's revenue in the past year totalled $145.24 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.